Newsroom

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

PDF Version MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing...

read more +
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

PDF Version Refinancing replaces prior senior credit facility MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on...

read more +
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

PDF Version MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing...

read more +
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

PDF Version MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing...

read more +
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

PDF Version Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes MENLO PARK,...

read more +
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

PDF Version MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing...

read more +
Sight Sciences Appoints Matt Link as Chief Commercial Officer

PDF Version Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc....

read more +
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

PDF Version MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing...

read more +